Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

Rhea-AI Summary

Acumen Pharmaceuticals, Inc. will report first quarter financial results on May 9, 2023. The company will host a conference call and webcast to provide a business and financial update.

Positive

• Investors can expect to receive first quarter financial results from Acumen Pharmaceuticals, Inc. on May 9, 2023. The conference call and webcast will provide valuable insights into the company's business and financial performance.

Negative

• None.

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance. 

The webcast audio will be available via this link. 

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

FAQ

When will Acumen Pharmaceuticals, Inc. report its first quarter financial results?

Acumen Pharmaceuticals, Inc. will report its first quarter financial results on May 9, 2023.

What can investors expect from the conference call and webcast?

Investors can expect to receive a business and financial update during the conference call and webcast.

Where can I access the webcast audio?

The webcast audio will be available on the Investors section of Acumen Pharmaceuticals, Inc.'s website at www.acumenpharm.com.

How long will the webcast be available for?

The webcast will be available for at least 30 days in the Investors section of Acumen Pharmaceuticals, Inc.'s website.